[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![mupdatesbyscanx Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1926935883384553472.png) Market Updates by ScanX [@mupdatesbyscanx](/creator/twitter/mupdatesbyscanx) on x XXX followers
Created: 2025-07-23 12:19:24 UTC

Dr Reddys Laboratories (DRREDDY)
on NSE: 1247.40 (+0.60%)

Dr. Reddy's Reports XX% Revenue Growth to ₹8,545 Crore in Q1 FY26, Driven by NRT Portfolio and Branded Markets

View: Neutral

Dr Reddy's Laboratories reported consolidated revenues of ₹8,545 crore for Q1 FY26, up XX% year-over-year. Global Generics segment grew 10%, with Europe showing XXX% growth. North America revenues declined XX% due to price erosion in key products. Profit after Tax increased X% YoY to ₹1,418 crore. The company expanded partnerships for biosimilars and launched new products in India. Management remains focused on strengthening the base business amid challenges in the U.S. generics market.

Read more:

#Stocks #Market #DRREDDY

![](https://pbs.twimg.com/media/GwirFyebEAAncUB.jpg)

XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947994957861777527/c:line.svg)

**Related Topics**
[united states](/topic/united-states)
[quarterly earnings](/topic/quarterly-earnings)
[$drreddyns](/topic/$drreddyns)
[dr reddys](/topic/dr-reddys)

[Post Link](https://x.com/mupdatesbyscanx/status/1947994957861777527)